AnorMED completes enrollment in first of two phase 3 trials of Mozobil in stem cell transplant

By Lisa Kerner

Charlotte, N.C., July 10 - AnorMED Inc. completed enrollment in one of its two randomized, double-blind pivotal phase 3 trials evaluating Mozobil in a standard stem cell mobilization regimen.

The multiple myeloma trial reached its target enrollment of 300 patients. Recruitment continues for the second phase 3 trial in non-Hodgkin's lymphoma (NHL), with 241 of 300 patients.

The most recently enrolled patients will undergo their transplants over the next four to six weeks with a subsequent 100-day follow-up period required.

"We are pleased to have completed enrollment in our first phase 3 trial within our originally stated timelines," vice president of clinical development Gary Calandra said in a company news release.

"The next major milestone is the completion of enrollment of the NHL trial and then the announcement of topline data for both phase 3 trials which is planned by the second quarter of 2007."

Mozobil, a stem cell mobilizer, triggers the rapid movement of stem cells out of the bone marrow and into circulating blood for collection and use in a stem cell transplant.

Located in Vancouver, B.C., AnorMED discovers, develops and commercializes therapeutic products in the areas of hematology, oncology and HIV.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.